Sysmex Co. (OTCMKTS:SSMXY) Short Interest Update

Sysmex Co. (OTCMKTS:SSMXY) was the recipient of a large drop in short interest during the month of April. As of April 15th, there was short interest totalling 2,400 shares, a drop of 63.1% from the March 31st total of 6,500 shares. Based on an average daily trading volume, of 90,400 shares, the days-to-cover ratio is presently 0.0 days.

Sysmex Stock Performance

Shares of SSMXY stock traded up $0.04 during midday trading on Friday, hitting $15.89. The company had a trading volume of 72,811 shares, compared to its average volume of 58,249. The company’s 50 day simple moving average is $17.35 and its 200 day simple moving average is $17.50. Sysmex has a 52-week low of $15.02 and a 52-week high of $36.57. The stock has a market cap of $10.00 billion, a price-to-earnings ratio of 31.36 and a beta of 0.66. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.10 and a quick ratio of 2.27.

Sysmex (OTCMKTS:SSMXY) last announced its earnings results on Friday, February 9th. The company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.03). Sysmex had a net margin of 10.25% and a return on equity of 11.15%. The company had revenue of $770.84 million during the quarter. Research analysts anticipate that Sysmex will post 0.53 earnings per share for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.